Key Highlights:
- Mankind Pharma, through its Netherlands subsidiary, has agreed to invest €48 million for a 70% stake in Belgium-based Armed Cell Therapeutics (ACTx), expanding its presence in innovative cancer therapies and next-generation CAR-T cell treatments.
- ACTx’s pipeline includes programmes for non-Hodgkin lymphoma and small cell lung cancer. Its approach includes engineered CAR-T cells with additional payloads to strengthen and sustain anti-tumour activity, as well as exploring in vivo CAR-T cell generation.
- Led by R&D teams in the US and Europe, ACTx aims to address CAR-T limitations, including relapse, cell exhaustion and tumour resistance. Mankind plans to use the partnership to build a global innovative therapy pipeline and improve access to advanced treatments in India and worldwide.
Implications:
Mankind Pharma’s €48 million investment for a 70% stake in ACTx signals a strategic shift toward high-value oncology and next-generation CAR-T therapies. ACTx’s engineered and in vivo CAR-T approaches could differentiate its pipeline by addressing relapse and resistance, while clinical validation, development costs and manufacturing scalability will determine its competitiveness and long-term growth potential.
Source: Express Pharma
